학술논문
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Document Type
Article
Author
Wang, G.; Li, Y.; Xiong, C.; McDade, E.; Clifford, D.B.; Mills, S.L.; Santacruz, A.M.; Aschenbrenner, A.J.; Hassenstab, J.; Benzinger, T.L.S.; Gordon, B.A.; Fagan, A.M.; Coalier, K.A.; Libre-Guerra, J.J.; McCullough, A.; Joseph-Mathurin, N.; Chen, C.D.; Bateman, R.J.; Mummery, C.; Wendelberger, B.A.; Gauthier, S.; Masellis, M.; Holdridge, K.C.; Yaari, R.; Chatterjee, S.; Sims, J.; Delmar, P.; Kerchner, G.A.; Bittner, T.; Hofmann, C.
Source
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring . (Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14(1))
Subject
Language
English
ISSN
23528729